Skip to main content

Articles

Page 2 of 38

  1. Muscle wasting is a consequence of physiological changes or a pathology characterized by increased catabolic activity that leads to progressive loss of skeletal muscle mass and strength. Numerous diseases, inc...

    Authors: Tania Setiawan, Ita Novita Sari, Yoseph Toni Wijaya, Nadya Marcelina Julianto, Jabir Aliyu Muhammad, Hyeok Lee, Ji Heon Chae and Hyog Young Kwon
    Citation: Journal of Hematology & Oncology 2023 16:54
    Content type: Review Published on:

  2. Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhib...

    Authors: Andrew Wang, James Liu and Jeffrey J. Pu
    Citation: Journal of Hematology & Oncology 2023 16:53
    Content type: Correspondence Published on:

  3. Authors: Muhammad Elnaggar, Sarita Agte, Paula Restrepo, Meghana Ram, David Melnekoff, Christos Adamopoulos, Mark M. Stevens, Katerina Kappes, Violetta Leshchenko, Daniel Verina, Sundar Jagannath, Poulikos I. Poulikakos, Samir Parekh and Alessandro Laganà
    Citation: Journal of Hematology & Oncology 2023 16:52
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2022 15:109

  5. QL1706 (PSB205) is a single bifunctional MabPair (a novel technical platform) product consisting of two engineered monoclonal antibodies (anti-PD-1 IgG4 and anti-CTLA-4 IgG1), with a shorter elimination half-l...

    Authors: Yuanyuan Zhao, Yuxiang Ma, Aimin Zang, Ying Cheng, Yiping Zhang, Xiangcai Wang, Zhendong Chen, Song Qu, Jianbo He, Chuanben Chen, Chuan Jin, Dongyuan Zhu, Qingshan Li, Xianling Liu, Wuyun Su, Yi Ba…
    Citation: Journal of Hematology & Oncology 2023 16:50
    Content type: Research Published on:

  6. Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate ther...

    Authors: Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reaves, Montreh Tavakkoli, Kathryn Lindsey, Irl Brian Greenwell, Emily Hansinger, Colin Thomas, Sayan Mullick Chowdhury, Kaitlin Annunzio…
    Citation: Journal of Hematology & Oncology 2023 16:49
    Content type: Correspondence Published on:

  7. Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiologic agent of several human cancers, including Kaposi’s sarcoma (KS) and primary effusion lymphoma (PEL), which preferentially arise in immunocompromi...

    Authors: Jungang Chen, Zhen Lin, Jiao Song, Karlie Plaisance-Bonstaff, Jennifer James, Shengyu Mu, Steven R. Post, Lu Dai and Zhiqiang Qin
    Citation: Journal of Hematology & Oncology 2023 16:48
    Content type: Correspondence Published on:

  8. COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) strain and variants BA.4/5 after the primary 2-dose and booster vaccination remained unkno...

    Authors: Chen Chen, Liyuan Dai, Cuiling Zheng, Haolong Li, Xiaomeng Li, Mengwei Yang, Ruyun Gao, Jiarui Yao, Zhishang Zhang, Yuankai Shi and Xiaohong Han
    Citation: Journal of Hematology & Oncology 2023 16:47
    Content type: Correspondence Published on:

  9. Bone metastasis is the leading cause of death in patients with prostate cancer (PCa) and currently has no effective treatment. Disseminated tumor cells in bone marrow often obtain new characteristics to cause ...

    Authors: Xinyu Ye, Xin Huang, Xing Fu, Xiao Zhang, Risheng Lin, Wen Zhang, Jian Zhang and Yi Lu
    Citation: Journal of Hematology & Oncology 2023 16:46
    Content type: Research Published on:

  10. Dysregulation of the Notch signaling pathway, which is highly conserved across species, can drive aberrant epigenetic modification, transcription, and translation. Defective gene regulation caused by dysregula...

    Authors: Xinxin Li, Xianchun Yan, Yufeng Wang, Balveen Kaur, Hua Han and Jianhua Yu
    Citation: Journal of Hematology & Oncology 2023 16:45
    Content type: Review Published on:

  11. Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy. This mature analysis explores the benefit of the addition of sequential b...

    Authors: Hagop Kantarjian, Fadi G. Haddad, Nitin Jain, Koji Sasaki, Nicholas J. Short, Sanam Loghavi, Rashmi Kanagal-Shamanna, Jeffrey Jorgensen, Issa Khouri, Partow Kebriaei, Yesid Alvarado, Tapan Kadia, Shilpa Paul, Guillermo Garcia-Manero, Bouthaina Dabaja, Musa Yilmaz…
    Citation: Journal of Hematology & Oncology 2023 16:44
    Content type: Research Published on:

  12. Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop T...

    Authors: Carolina Pavlovsky, Bianca Vasconcelos Cordoba, María Belén Sanchez, Beatriz Moiraghi, Ana Varela, Rosario Custidiano, Isolda Fernandez, Maria Josefina Freitas, Maria Verónica Ventriglia, Georgina Bendek, Romina Mariano, María José Mela Osorio, Miguel Angel Pavlovsky, Ana García de Labanca, Cecilia Foncuberta, Isabel Giere…
    Citation: Journal of Hematology & Oncology 2023 16:43
    Content type: Correspondence Published on:

  13. Relapsed or refractory acute myeloid leukemia (R/R AML) has a dismal prognosis. The aim of this study was to investigate the activity and tolerability of venetoclax combined with azacitidine plus homoharringto...

    Authors: Hua Jin, Yu Zhang, Sijian Yu, Xin Du, Na Xu, Ruoyang Shao, Dongjun Lin, Yanqiu Chen, Jie Xiao, Zhiqiang Sun, Lan Deng, Xinquan Liang, Hongyu Zhang, Ziwen Guo, Min Dai, Pengcheng Shi…
    Citation: Journal of Hematology & Oncology 2023 16:42
    Content type: Research Published on:

  15. Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unpr...

    Authors: Si-Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si-Yang Liu, Yangqiu Li and Yi-Long Wu
    Citation: Journal of Hematology & Oncology 2023 16:40
    Content type: Review Published on:

  16. Cancer patients, due to their immunocompromised status, are at an increased risk for severe SARS-CoV-2 infection. Since severe SARS-CoV-2 infection causes multiple organ damage through IL-6-mediated inflammati...

    Authors: Yan Leyfman, Nancy Emmanuel, Gayathri P. Menon, Muskan Joshi, William B. Wilkerson, Jared Cappelli, Timothy K. Erick, Chandler H. Park and Pushpa Sharma
    Citation: Journal of Hematology & Oncology 2023 16:39
    Content type: Review Published on:

  18. Recurrent mutations in TP53, RAS pathway and JAK2 genes were shown to be highly prognostic of allogeneic hematopoietic cell transplant (alloHCT) outcomes in myelodysplastic syndromes (MDS). However, a signific...

    Authors: Tao Zhang, Paul Auer, Jing Dong, Corey Cutler, Amy E. Dezern, Shahinaz M. Gadalla, H. Joachim Deeg, Aziz Nazha, Karen-Sue Carlson, Stephen Spellman, Yung-Tsi Bolon and Wael Saber
    Citation: Journal of Hematology & Oncology 2023 16:37
    Content type: Correspondence Published on:

  21. Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with refractory or relapsed T-cell acute lymphoblastic leukemia (r/r T-ALL), in a previous p...

    Authors: Yue Tan, Lingling Shan, Liping Zhao, Biping Deng, Zhuojun Ling, Yanlei Zhang, Shuixiu Peng, Jinlong Xu, Jiajia Duan, Zelin Wang, Xinjian Yu, Qinlong Zheng, Xiuwen Xu, Zhenglong Tian, Yibing Zhang, Jiecheng Zhang…
    Citation: Journal of Hematology & Oncology 2023 16:34
    Content type: Research Published on:

  22. In human cells BRAF oncogene is invariably expressed as a mix of two coding transcripts: BRAF-ref and BRAF-X1. These two mRNA isoforms, remarkably different in the sequence and length of their 3′UTRs, are potenti...

    Authors: Andrea Marranci, Antonella Prantera, Simona Masotti, Raffaella De Paolo, Caterina Baldanzi, Maurizio S. Podda, Serena Mero, Marianna Vitiello, Cinzia Franchin, Mariavittoria Laezza, Laura Comelli, Giorgio Arrigoni, Tiziana Cervelli, Giovanna Del Pozzo and Laura Poliseno
    Citation: Journal of Hematology & Oncology 2023 16:33
    Content type: Correspondence Published on:

  23. Only few studies have analyzed the efficacy of tixagevimab/cilgavimab to prevent severe Coronavirus disease 2019 (COVID-19) and related complications in hematologic malignancies (HM) patients. Here, we report ...

    Authors: Francesco Marchesi, Jon Salmanton-García, Caterina Buquicchio, Federico Itri, Caroline Besson, Julio Dávila-Valls, Sonia Martín-Pérez, Luana Fianchi, Laman Rahimli, Giuseppe Tarantini, Federica Irene Grifoni, Mariarita Sciume, Jorge Labrador, Raul Cordoba, Alberto López-García, Nicola S. Fracchiolla…
    Citation: Journal of Hematology & Oncology 2023 16:32
    Content type: Correspondence Published on:

  25. Cancer cachexia is a deadly wasting syndrome that accompanies various diseases (including ~ 50% of cancers). Clinical studies have established that cachexia is not a nutritional deficiency and is linked to exp...

    Authors: Dong Wang, Xiaohui Li, Defeng Jiao, Ying Cai, Liting Qian, Yiqing Shen, Yichen Lu, Yonggang Zhou, Binqing Fu, Rui Sun, Zhigang Tian, Xiaohu Zheng and Haiming Wei
    Citation: Journal of Hematology & Oncology 2023 16:30
    Content type: Research Published on:

  26. Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induct...

    Authors: Rahul S. Bhansali, Keith W. Pratz and Catherine Lai
    Citation: Journal of Hematology & Oncology 2023 16:29
    Content type: Review Published on:

  27. The tumor microenvironment (TME) has been extensively investigated; however, it is complex and remains unclear, especially in elderly patients. Senescence is a cellular response to a variety of stress signals,...

    Authors: Binghao Zhao, Bo Wu, Nan Feng, Xiang Zhang, Xin Zhang, Yiping Wei and Wenxiong Zhang
    Citation: Journal of Hematology & Oncology 2023 16:28
    Content type: Review Published on:

  28. Acute myeloid leukemia (AML) is a deadly hematological malignancy. Cellular morphology detection of bone marrow smears based on the French–American–British (FAB) classification system remains an essential crit...

    Authors: Zebin Yu, Jianhu Li, Xiang Wen, Yingli Han, Penglei Jiang, Meng Zhu, Minmin Wang, Xiangli Gao, Dan Shen, Ting Zhang, Shuqi Zhao, Yijing Zhu, Jixiang Tong, Shuchong Yuan, HongHu Zhu, He Huang…
    Citation: Journal of Hematology & Oncology 2023 16:27
    Content type: Correspondence Published on:

  29. Treatment options specifically for patients with locally advanced pancreatic adenocarcinoma (LAPC) are scare and chemotherapy alone delivers limited efficacy. Immunotherapy and radiotherapy are potential effec...

    Authors: Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen and Zhenwei Peng
    Citation: Journal of Hematology & Oncology 2023 16:26
    Content type: Correspondence Published on:

  30. There are situations where non-first-degree (NFD) related donors have to be considered as alternatives to first-degree (FD) related donors for haploidentical hematopoietic cell transplantation (HAPLO). However...

    Authors: Yishan Ye, Myriam Labopin, Jia Chen, Zafer Gulbas, Xi Zhang, Yener Koc, Didier Blaise, Fabio Ciceri, Emmanuelle Polge, Mohamed Houhou, Lin Li, Yi Luo, Depei Wu, He Huang, Mohamad Mohty and Norbert-Claude Gorin
    Citation: Journal of Hematology & Oncology 2023 16:25
    Content type: Correspondence Published on:

  32. The immunological composition of the tumor microenvironment has a decisive influence on the biological course of cancer and is therefore of profound clinical relevance. In this study, we analyzed the cooperati...

    Authors: Sandra Genduso, Vera Freytag, Daniela Schetler, Lennart Kirchner, Alina Schiecke, Hanna Maar, Daniel Wicklein, Florian Gebauer, Katharina Bröker, Christine Stürken, Karin Milde-Langosch, Leticia Oliveira-Ferrer, Franz L. Ricklefs, Florian Ewald, Gerrit Wolters-Eisfeld, Kristoffer Riecken…
    Citation: Journal of Hematology & Oncology 2023 16:23
    Content type: Research Published on:

  33. Progress in the research and therapy of adult acute lymphoblastic leukemia (ALL) is accelerating. This analysis summarizes the data derived from the clinical trials conducted at MD Anderson between 1985 and 20...

    Authors: Elias Jabbour, Nicholas J. Short, Nitin Jain, Fadi G. Haddad, Mary Alma Welch, Farhad Ravandi and Hagop Kantarjian
    Citation: Journal of Hematology & Oncology 2023 16:22
    Content type: Review Published on:

  34. Despite mitochondrial DNA (mtDNA) mutations are common events in cancer, their global frequency and clinical impact have not been comprehensively characterized in patients with myelodysplastic neoplasia (also ...

    Authors: Jing Dong, Christopher Staffi Buradagunta, Tao Zhang, Stephen Spellman, Yung-Tsi Bolon, Amy E. DeZern, Shahinaz M. Gadalla, H. Joachim Deeg, Aziz Nazha, Corey Cutler, Chao Cheng, Raul Urrutia, Paul Auer and Wael Saber
    Citation: Journal of Hematology & Oncology 2023 16:21
    Content type: Correspondence Published on:

  36. TP53 mutations, which are present in 5% to 10% of patients with acute myeloid leukemia (AML), are associated with treatment resistance and poor outcomes. First-line therapies for TP53-mutated (TP53m) AML consist ...

    Authors: Naval G. Daver, Shahed Iqbal, Camille Renard, Rebecca J. Chan, Ken Hasegawa, Hao Hu, Preston Tse, Jiajun Yan, Michael J. Zoratti, Feng Xie and Giridharan Ramsingh
    Citation: Journal of Hematology & Oncology 2023 16:19
    Content type: Research Published on:

  38. Developments in investigational agents and novel regimens in acute myeloid leukemia (AML) were reported in the 2022 American Society of Hematology (ASH) annual meeting. Encouraging efficacy data were presented...

    Authors: Katherine W. DiNardo, Thomas W. LeBlanc and Hui Chen
    Citation: Journal of Hematology & Oncology 2023 16:17
    Content type: Correspondence Published on:

  39. The immunoglobulin J chain (Jchain) is highly expressed in the majority of multiple myeloma (MM), and Jchain-derived peptides presented in HLA molecules may be suitable antigens for T-cell therapy of MM.

    Authors: Miranda H. Meeuwsen, Anne K. Wouters, Tassilo L. A. Wachsmann, Renate S. Hagedoorn, Michel G. D. Kester, Dennis F. G. Remst, Dirk M. van der Steen, Arnoud H. de Ru, Els P. van Hees, Martijn Kremer, Marieke Griffioen, Peter A. van Veelen, J. H. Frederik Falkenburg and Mirjam H. M. Heemskerk
    Citation: Journal of Hematology & Oncology 2023 16:16
    Content type: Research Published on:

  40. The acute myeloid leukemia (AML) patients obtain limited benefits from current immune checkpoint blockades (ICBs), although immunotherapy have achieved encouraging success in numerous cancers. Here, we found t...

    Authors: Jianshan Mo, Lin Deng, Keren Peng, Shumin Ouyang, Wen Ding, Linlin Lou, Ziyou Lin, Jianzheng Zhu, Jingwei Li, Qiyi Zhang, Pengyan Wang, Yuanzhen Wen, Xiaobing Chen, Peibin Yue, Jin-Jian Lu, Kai Zhu…
    Citation: Journal of Hematology & Oncology 2023 16:15
    Content type: Correspondence Published on:

  42. Authors: Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu, Bingcheng Liu, Yanli Zhang, Li Meng, Huanling Zhu, Xin Du, Suning Chen, Yang Liang, Yu Hu, Xiaoli Liu, Yongping Song, Lichuang Men…
    Citation: Journal of Hematology & Oncology 2023 16:13
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2022 15:113

  44. Authors: Chiara Fallerini, Sergio Daga, Elisa Benetti, Nicola Picchiotti, Kristina Zguro, Francesca Catapano, Virginia Baroni, Simone Lanini, Alessandro Bucalossi, Giuseppe Marotta, Francesca Colombo, Margherita Baldassarri, Francesca Fava, Giada Beligni, Laura Di Sarno, Diana Alaverdian…
    Citation: Journal of Hematology & Oncology 2023 16:11
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2021 14:123

  45. The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Hapl...

    Authors: Frédéric Baron, Myriam Labopin, Johanna Tischer, Anna Maria Raiola, Jan Vydra, Didier Blaise, Patrizia Chiusolo, Friedrich Stölzel, Renato Fanin, Patrice Chevallier, Arnon Nagler, Fabio Ciceri and Mohamad Mohty
    Citation: Journal of Hematology & Oncology 2023 16:10
    Content type: Correspondence Published on:

  46. Selectively targeting leukemia stem cells (LSCs) is a promising approach in treating acute myeloid leukemia (AML), for which identification of such therapeutic targets is critical. Increasing lines of evidence...

    Authors: Xiao-Na Zhu, Yu-Sheng Wei, Qian Yang, Hao-Ran Liu, Zhe Zhi, Di Zhu, Li Xia, Deng-Li Hong, Yun Yu and Guo-Qiang Chen
    Citation: Journal of Hematology & Oncology 2023 16:9
    Content type: Research Published on:

  47. RIG-I-like receptors (RLRs) are intracellular pattern recognition receptors that detect viral or bacterial infection and induce host innate immune responses. The RLRs family comprises retinoic acid-inducible g...

    Authors: Yangfu Jiang, Hongying Zhang, Jiao Wang, Jinzhu Chen, Zeyu Guo, Yongliang Liu and Hui Hua
    Citation: Journal of Hematology & Oncology 2023 16:8
    Content type: Review Published on:

  48. The prognosis of pancreatic ductal adenocarcinoma (PDAC) is one of the most dismal of all cancers and the median survival of PDAC patients is only 6–8 months after diagnosis. While decades of research effort h...

    Authors: Yi Han, Pascal Drobisch, Alexander Krüger, Doreen William, Konrad Grützmann, Lukas Böthig, Heike Polster, Lena Seifert, Adrian M. Seifert, Marius Distler, Mathieu Pecqueux, Carina Riediger, Verena Plodeck, Heiner Nebelung, Georg F. Weber, Christian Pilarsky…
    Citation: Journal of Hematology & Oncology 2023 16:7
    Content type: Research Published on:

  49. Despite significant progress in clinical management, drug resistance remains a major obstacle. Recent research based on protein degradation to restrain drug resistance has attracted wide attention, and several...

    Authors: Hui Ming, Bowen Li, Jingwen Jiang, Siyuan Qin, Edouard C. Nice, Weifeng He, Tingyuan Lang and Canhua Huang
    Citation: Journal of Hematology & Oncology 2023 16:6
    Content type: Review Published on:

  50. T cell receptor (TCR)-T cells possess similar effector function, but milder and more durable signal activation compared with chimeric antigen receptor-T cells. TCR-T cell therapy is another active field of cel...

    Authors: Chenggong Li, Fen Zhou, Jing Wang, Qi Chang, Mengyi Du, Wenjing Luo, Yinqiang Zhang, Jia Xu, Lu Tang, Huiwen Jiang, Lin Liu, Haiming Kou, Cong Lu, Danying Liao, Jianghua Wu, Qiuzhe Wei…
    Citation: Journal of Hematology & Oncology 2023 16:5
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2022 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    74 days submission to accept (Median)

    2022 Usage 
    2,836,875 downloads
    9,883 Altmetric mentions 

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us